{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:06:42Z","timestamp":1789686402196,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573158"],"award-info":[{"award-number":["82573158"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472367"],"award-info":[{"award-number":["82472367"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011447","name":"Science and Technology Department of Henan Province","doi-asserted-by":"publisher","award":["242301420075"],"award-info":[{"award-number":["242301420075"]}],"id":[{"id":"10.13039\/501100011447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009101","name":"Education Department of Henan Province","doi-asserted-by":"publisher","award":["25A320006"],"award-info":[{"award-number":["25A320006"]}],"id":[{"id":"10.13039\/501100009101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Homeobox C9 (HOXC9) plays a critical role in tumor progression. However, its function and regulatory mechanisms in esophageal squamous cell carcinoma (ESCC) remain unclear. Here, we found that HOXC9 expression was significantly upregulated in ESCC (|log\n                    <jats:sub>2<\/jats:sub>\n                    FC|\u2009\u2265\u20092,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05) and was positively associated with poor prognosis in ESCC patients (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.032). HOXC9 promoted ESCC progression in vitro and in vivo. Mechanistically, HOXC9 directly activated\n                    <jats:italic>ovarian tumor deubiquitinase 1<\/jats:italic>\n                    (\n                    <jats:italic>OTUD1<\/jats:italic>\n                    ) transcription by binding to its promoter region. This activation enhanced OTUD1-mediated fatty acid binding protein 5 (FABP5) deubiquitination, increasing FABP5 protein stability, reducing lipid droplet accumulation, and elevating glycerol and free fatty acid levels (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05), thereby accelerating ESCC cell proliferation and migration. In addition, HOXC9-OTUD1-FABP5 signaling was closely linked to the clinicopathological grade of ESCC patients. Our study comprehensively reveals the mechanism by which HOXC9 accelerates ESCC progression, and identifies potential biomarkers and therapeutic targets for the pathogenesis and clinical treatment of ESCC.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-09013-4","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:27:55Z","timestamp":1782822475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HOXC9 accelerates esophageal squamous cell carcinoma progression via OTUD1-FABP5-mediated lipid metabolic reprogramming"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6462-1007","authenticated-orcid":false,"given":"Cai","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3163-1691","authenticated-orcid":false,"given":"Yangyang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilu","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"9013_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"9013_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11912-021-01153-4","volume":"24","author":"JK Waters","year":"2022","unstructured":"Waters JK, Reznik SI. Update on management of squamous cell esophageal cancer. Curr Oncol Rep. 2022;24:375\u201385.","journal-title":"Curr Oncol Rep"},{"key":"9013_CR3","first-page":"87","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"9013_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400\u201312.","journal-title":"Lancet"},{"key":"9013_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100789","volume":"8","author":"HC Puhr","year":"2023","unstructured":"Puhr HC, Prager GW, Ilhan-Mutlu A. How we treat esophageal squamous cell carcinoma. ESMO Open. 2023;8:100789.","journal-title":"ESMO Open"},{"key":"9013_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/0092-8674(92)90471-N","volume":"68","author":"W McGinnis","year":"1992","unstructured":"McGinnis W, Krumlauf R. Homeobox genes and axial patterning. Cell. 1992;68:283\u2013302.","journal-title":"Cell"},{"key":"9013_CR7","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/bies.200800229","volume":"31","author":"S Merabet","year":"2009","unstructured":"Merabet S, Hudry B, Saadaoui M, Graba Y. Classification of sequence signatures: a guide to Hox protein function. BioEssays New Rev Mol Cell Dev Biol. 2009;31:500\u201311.","journal-title":"BioEssays New Rev Mol Cell Dev Biol"},{"key":"9013_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.7150\/ijbs.11431","volume":"11","author":"JY Lee","year":"2015","unstructured":"Lee JY, Hur H, Yun HJ, Kim Y, Yang S, Kim SI, et al. HOXB5 promotes the proliferation and invasion of breast cancer cells. Int J Biol Sci. 2015;11:701\u201311.","journal-title":"Int J Biol Sci"},{"key":"9013_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.770428","volume":"11","author":"Y Feng","year":"2021","unstructured":"Feng Y, Zhang T, Wang Y, Xie M, Ji X, Luo X, et al. Homeobox genes in cancers: from carcinogenesis to recent therapeutic intervention. Front Oncol. 2021;11:770428.","journal-title":"Front Oncol"},{"key":"9013_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.145308","volume":"768","author":"V Kumar","year":"2021","unstructured":"Kumar V, Sekar M, Sarkar P, Acharya KK, Thirumurugan K. Dynamics of HOX gene expression and regulation in adipocyte development. Gene. 2021;768:145308.","journal-title":"Gene"},{"key":"9013_CR11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00109-014-1181-y","volume":"92","author":"S Bhatlekar","year":"2014","unstructured":"Bhatlekar S, Fields JZ, Boman BM. HOX genes and their role in the development of human cancers. J Mol Med. 2014;92:811\u201323.","journal-title":"J Mol Med"},{"key":"9013_CR12","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.3390\/nu12082162","volume":"12","author":"A Efremova","year":"2020","unstructured":"Efremova A, Colleluori G, Thomsky M, Perugini J, Protasoni M, Reguzzoni M, et al. Biomarkers of browning in cold exposed Siberian adults. Nutrients. 2020;12:2162.","journal-title":"Nutrients"},{"key":"9013_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-024-10231-3","volume":"25","author":"L He","year":"2024","unstructured":"He L, Feng X, Hu C, Liu S, Sheng H, Cai B, et al. HOXA9 gene inhibits proliferation and differentiation and promotes apoptosis of bovine preadipocytes. BMC Genom. 2024;25:358.","journal-title":"BMC Genom"},{"key":"9013_CR14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.7150\/jca.13894","volume":"7","author":"H Hur","year":"2016","unstructured":"Hur H, Lee JY, Yang S, Kim JM, Park AE, Kim MH. HOXC9 induces phenotypic switching between proliferation and invasion in breast cancer cells. J Cancer. 2016;7:768\u201373.","journal-title":"J Cancer"},{"key":"9013_CR15","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1111\/cas.15043","volume":"112","author":"Y Tang","year":"2021","unstructured":"Tang Y, Wang T, Yu Y, Yan Y, Wu C. Upregulation of HOXC9 generates interferon-gamma resistance in gastric cancer by inhibiting the DAPK1\/RIG1\/STAT1 axis. Cancer Sci. 2021;112:3455\u201368.","journal-title":"Cancer Sci"},{"key":"9013_CR16","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1007\/s10147-020-01772-0","volume":"25","author":"XF Zhao","year":"2020","unstructured":"Zhao XF, Yang YS, Park YK. HOXC9 overexpression is associated with gastric cancer progression and a prognostic marker for poor survival in gastric cancer patients. Int J Clin Oncol. 2020;25:2044\u201354.","journal-title":"Int J Clin Oncol"},{"key":"9013_CR17","first-page":"4841","volume":"16","author":"L Liu","year":"2024","unstructured":"Liu L, Zhang Z, Jiang C, Zhu Y, Han R, Wu L, et al. HOXC9 characterizes a suppressive tumor immune microenvironment and integration with multiple immune biomarkers predicts response to PD-1 blockade plus chemotherapy in lung adenocarcinoma. Aging. 2024;16:4841\u201361.","journal-title":"Aging"},{"key":"9013_CR18","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1152\/physrev.00002.2013","volume":"93","author":"MJ Clague","year":"2013","unstructured":"Clague MJ, Barsukov I, Coulson JM, Liu H, Rigden DJ, Urb\u00e9 S. Deubiquitylases from genes to organism. Physiol Rev. 2013;93:1289\u2013315.","journal-title":"Physiol Rev"},{"key":"9013_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188736","volume":"1877","author":"HB Park","year":"2022","unstructured":"Park HB, Baek KH. E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers. Biochim Biophys Acta Rev Cancer. 2022;1877:188736.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"9013_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","volume":"23","author":"G Dewson","year":"2023","unstructured":"Dewson G, Eichhorn PJA, Komander D. Deubiquitinases in cancer. Nat Rev Cancer. 2023;23:842\u201362.","journal-title":"Nat Rev Cancer"},{"key":"9013_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02029-7","volume":"8","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Fan Y, Xie F, Zhou H, Jin K, Shao L, et al. Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7. Nat Commun. 2017;8:2116.","journal-title":"Nat Commun"},{"key":"9013_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45698-x","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Qiang Y, Fan J, Zheng Q, Yan L, Fan G, et al. Aggresome formation promotes ASK1\/JNK signaling activation and stemness maintenance in ovarian cancer. Nat Commun. 2024;15:1321.","journal-title":"Nat Commun"},{"key":"9013_CR23","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.7150\/ijbs.68980","volume":"18","author":"W Liu","year":"2022","unstructured":"Liu W, Yan B, Yu H, Ren J, Peng M, Zhu L, et al. OTUD1 stabilizes PTEN to inhibit the PI3K\/AKT and TNF-alpha\/NF-kappaB signaling pathways and sensitize ccRCC to TKIs. Int J Biol Sci. 2022;18:1401\u201314.","journal-title":"Int J Biol Sci"},{"key":"9013_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40880-018-0301-4","volume":"38","author":"C Cheng","year":"2018","unstructured":"Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun. 2018;38:27.","journal-title":"Cancer Commun"},{"key":"9013_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.tem.2023.10.004","volume":"35","author":"LC Lin","year":"2024","unstructured":"Lin LC, Liu ZY, Yang JJ, Zhao JY, Tao H. Lipid metabolism reprogramming in cardiac fibrosis. Trends Endocrinol Metab. 2024;35:164\u201375.","journal-title":"Trends Endocrinol Metab"},{"key":"9013_CR26","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.7150\/thno.82920","volume":"13","author":"K Yang","year":"2023","unstructured":"Yang K, Wang X, Song C, He Z, Wang R, Xu Y, et al. The role of lipid metabolic reprogramming in tumor microenvironment. Theranostics. 2023;13:1774\u2013808.","journal-title":"Theranostics"},{"key":"9013_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103628","volume":"28","author":"W George Warren","year":"2023","unstructured":"George Warren W, Osborn M, Yates A, Wright K, O\u2019Sullivan SE. The emerging role of fatty acid binding protein 5 (FABP5) in cancers. Drug Discov today. 2023;28:103628.","journal-title":"Drug Discov today"},{"key":"9013_CR28","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1016\/j.drudis.2020.09.018","volume":"25","author":"SE O\u2019Sullivan","year":"2020","unstructured":"O\u2019Sullivan SE, Kaczocha M. FABP5 as a novel molecular target in prostate cancer. Drug Discov today. 2020;25:2056\u201361.","journal-title":"Drug Discov today"},{"key":"9013_CR29","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.7150\/thno.44868","volume":"10","author":"C Zhang","year":"2020","unstructured":"Zhang C, Liao Y, Liu P, Du Q, Liang Y, Ooi S, et al. FABP5 promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism. Theranostics. 2020;10:6561\u201380.","journal-title":"Theranostics"},{"key":"9013_CR30","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.bbalip.2018.06.010","volume":"1863","author":"S Senga","year":"2018","unstructured":"Senga S, Kobayashi N, Kawaguchi K, Ando A, Fujii H. Fatty acid-binding protein 5 (FABP5) promotes lipolysis of lipid droplets, de novo fatty acid (FA) synthesis and activation of nuclear factor-kappa B (NF-\u03baB) signaling in cancer cells. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863:1057\u201367.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"9013_CR31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1158\/0008-5472.CAN-22-2156","volume":"83","author":"GC Zhang","year":"2023","unstructured":"Zhang GC, Yu XN, Guo HY, Sun JL, Liu ZY, Zhu JM, et al. PRP19 enhances esophageal squamous cell carcinoma progression by reprogramming SREBF1-dependent fatty acid metabolism. Cancer Res. 2023;83:521\u201337.","journal-title":"Cancer Res"},{"key":"9013_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102544","volume":"58","author":"T Tian","year":"2022","unstructured":"Tian T, Lu Y, Lin J, Chen M, Qiu H, Zhu W, et al. CPT1A promotes anoikis resistance in esophageal squamous cell carcinoma via redox homeostasis. Redox Biol. 2022;58:102544.","journal-title":"Redox Biol"},{"key":"9013_CR33","doi-asserted-by":"publisher","first-page":"190122","DOI":"10.7754\/Clin.Lab.2019.190122","volume":"65","author":"M Hu","year":"2019","unstructured":"Hu M, Ou-Yang W, Jing D, Chen R. Clinical prognostic significance of HOXC9 expression in patients with colorectal cancer. Clin Lab. 2019;65:190122.","journal-title":"Clin Lab"},{"key":"9013_CR34","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/neuonc\/nov281","volume":"18","author":"F Xuan","year":"2016","unstructured":"Xuan F, Huang M, Liu W, Ding H, Yang L, Cui H. Homeobox C9 suppresses Beclin1-mediated autophagy in glioblastoma by directly inhibiting the transcription of death-associated protein kinase 1. Neuro Oncol. 2016;18:819\u201329.","journal-title":"Neuro Oncol"},{"key":"9013_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01262-x","volume":"19","author":"T Sun","year":"2020","unstructured":"Sun T, Liu Z, Yang Q. The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer. 2020;19:146.","journal-title":"Mol Cancer"},{"key":"9013_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33285-x","volume":"13","author":"D Shi","year":"2022","unstructured":"Shi D, Wu X, Jian Y, Wang J, Huang C, Mo S, et al. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nat Commun. 2022;13:5644.","journal-title":"Nat Commun"},{"key":"9013_CR37","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1158\/0008-5472.CAN-19-2388","volume":"80","author":"H Zhu","year":"2020","unstructured":"Zhu H, Yan F, Yuan T, Qian M, Zhou T, Dai X, et al. USP10 promotes proliferation of hepatocellular carcinoma by deubiquitinating and stabilizing YAP\/TAZ. Cancer Res. 2020;80:2204\u201316.","journal-title":"Cancer Res"},{"key":"9013_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-024-00555-1","volume":"19","author":"J Wang","year":"2024","unstructured":"Wang J, Ye J, Liu R, Chen C, Wang W. TRIM47 drives gastric cancer cell proliferation and invasion by regulating CYLD protein stability. Biol Direct. 2024;19:106.","journal-title":"Biol Direct"},{"key":"9013_CR39","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41418-022-01104-x","volume":"30","author":"YF Cao","year":"2023","unstructured":"Cao YF, Xie L, Tong BB, Chu MY, Shi WQ, Li X, et al. Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma. Cell Death Differ. 2023;30:527\u201343.","journal-title":"Cell Death Differ"},{"key":"9013_CR40","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.intimp.2016.11.013","volume":"42","author":"SF Gao","year":"2017","unstructured":"Gao SF, Zhong B, Lin D. Regulation of T helper cell differentiation by E3 ubiquitin ligases and deubiquitinating enzymes. Int Immunopharmacol. 2017;42:150\u20136.","journal-title":"Int Immunopharmacol"},{"key":"9013_CR41","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1038\/s41418-022-00971-8","volume":"29","author":"X Han","year":"2022","unstructured":"Han X, Ren C, Lu C, Qiao P, Yang T, Yu Z. Deubiquitination of MYC by OTUB1 contributes to HK2 mediated glycolysis and breast tumorigenesis. Cell Death Differ. 2022;29:1864\u201373.","journal-title":"Cell Death Differ"},{"key":"9013_CR42","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.7150\/ijbs.85285","volume":"19","author":"M Ye","year":"2023","unstructured":"Ye M, Hu C, Chen T, Yu P, Chen J, Lu F, et al. FABP5 suppresses colorectal cancer progression via mTOR-mediated autophagy by decreasing FASN expression. Int J Biol Sci. 2023;19:3115\u201327.","journal-title":"Int J Biol Sci"},{"key":"9013_CR43","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.devcel.2021.04.013","volume":"56","author":"LA Broadfield","year":"2021","unstructured":"Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt SM. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev Cell. 2021;56:1363\u201393.","journal-title":"Dev Cell"},{"key":"9013_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008811","volume":"12","author":"Y Chen","year":"2024","unstructured":"Chen Y, Zhou Y, Ren R, Chen Y, Lei J, Li Y. Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinoma. J Immunother Cancer. 2024;12:e008811.","journal-title":"J Immunother Cancer"},{"key":"9013_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42332-0","volume":"14","author":"JJ Li","year":"2023","unstructured":"Li JJ, Wang JH, Tian T, Liu J, Zheng YQ, Mo HY, et al. The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer. Nat Commun. 2023;14:6690.","journal-title":"Nat Commun"},{"key":"9013_CR46","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s13402-025-01079-0","volume":"48","author":"H Liang","year":"2025","unstructured":"Liang H, Liu X, Guo W, Xiong W, Ren D, Liu W. OTUD1 downregulates PD-L1 expression by deubiquitinating STAT3 and promotes the immune response in ccRCC. Cell Oncol. 2025;48:1349\u201361.","journal-title":"Cell Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09013-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09013-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09013-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:48:06Z","timestamp":1789685286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09013-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9013"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09013-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All procedures involving animal and human experiments were performed in accordance with the relevant guidelines and regulations. The animal experiments were approved by the Biomedical Ethics Committee of the First Affiliated Hospital of Zhengzhou University (Approval No. ZZU-LAC20250522). Tissue microarrays (HEso-Squ030PG-01 and HEsoS030PG02) were obtained from Shanghai Outdo Biotech (Shanghai, China) and the procedures were approved by the Clinical Research Ethics Committee, Outdo Biotech (Approval Nos. SHYJS-CP-1404004 and SHYJS-CP-1501002). All patients signed written informed consent forms.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"809"}}